Product Description
UCART-22 is being developed by Cellectis for the treatment of patients with Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04150497?term=UCART-22&draw=2&rank=1)
Mechanisms of Action: CAR-T, CD22
Novel Mechanism: Yes
Modality: Allogeneic CAR-T
Route of Administration: N/A
FDA Designation: Orphan Drug - Acute Leukemia|Acute Lymphoid Leukemia|Leukemia|Lymphoid LeukemiaOrphan Drug - Acute Lymphoid Leukemia *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cellectis
Company Location: PARIS, LLE-DE-FRANCE I0 75013
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Italy, Spain, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Cellectis presented P1 Acute Lymphoid Leukemia results on 2025-10-16 for Lasmecabtagene timgedleucel
- Clinical Outcomes Reported - Cellectis announced they will present P1 Acute Lymphoid Leukemia results in 3Q25 for Lasmecabtagene timgedleucel
- Clinical Outcomes Expected - Cellectis announced they will present P1 Leukemia results in YE25 for Lasmecabtagene timgedleucel
Highest Development Phases
Phase 2: Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2020-004768-24 |
BALLI-01 | P2 |
Active, not recruiting |
Leukemia |
2040-08-08 |
2022-03-13 |
Treatments |
|
NCT04150497 |
BALLI-01 | P2 |
Recruiting |
Lymphoma, B-Cell|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
2026-06-30 |
2% |
2025-06-17 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2022-502305-15-00 |
2022-502305-15-00 | P2 |
Recruiting |
B-Cell Leukemia|Acute Lymphoid Leukemia |
2039-01-12 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/03/2025 |
News Article |
Cellectis to Present a Development Update for eti-cel at ASH 2025 |
|
10/16/2025 |
News Article |
Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL |
|
10/16/2025 |
News Article |
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers |
|
12/10/2024 |
News Article |
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) |